Enhancing the sensitivity of lung adenocarcinoma to immune therapeutic agents through <i>SPRED1</i>.

ABSTRACT:

Background

Programmed death-ligand 1 (PD-L1), a classic immune checkpoint, is a key target for immunotherapy. Research has demonstrated that Sprouty-related EVH1 domain-containing 1 (SPRED1), a negative regulator of the mitogen-activated protein kinase (MAPK) pathway, modulates PD-L1 expression and exhibits antitumor activity in diverse cancers. This study aimed to investigate the role and mechanisms of SPRED1 in enhancing the sensitivity of lung adenocarcinoma (LUAD) to immunotherapy and develop novel clinical therapeutic sensitization strategies.

Methods

In this study, bioinformatics technologies were employed to examine the interaction between SPRED1 and the survival prognosis of patients with LUAD and to identify key interacting molecules of <

SUBMITTER: Wu C 

PROVIDER: S-EPMC12432670 | biostudies-literature | 2025 Aug

REPOSITORIES: biostudies-literature